
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7796496/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Differential inflammatory responses of the native left and right ventricle associated with donor heart preservation. Physiological Reports, 2021, 9, e15004.	0.7	4
2	Complement as a Major Inducer of Harmful Events in Infectious Sepsis. Shock, 2020, 54, 595-605.	1.0	21
3	Role of Complement and Histones in Sepsis. Frontiers in Medicine, 2020, 7, 616957.	1.2	20
4	Requirement of Complement C6 for Intact Innate Immune Responses in Mice. Journal of Immunology, 2020, 205, 251-260.	0.4	17
5	Disruption of Neutrophil Extracellular Traps (NETs) Links Mechanical Strain to Post-traumatic Inflammation. Frontiers in Immunology, 2019, 10, 2148.	2.2	25
6	Complement and Its Consequences in Sepsis. , 2019, , 504-507.e1.		0
7	New strategies for treatment of infectious sepsis. Journal of Leukocyte Biology, 2019, 106, 187-192.	1.5	51
8	GM-CSF Administration Improves Defects in Innate Immunity and Sepsis Survival in Obese Diabetic Mice. Journal of Immunology, 2019, 202, 931-942.	0.4	22
9	Innate immune responses to trauma. Nature Immunology, 2018, 19, 327-341.	7.0	377
10	Harmful Roles of TLR3 and TLR9 in Cardiac Dysfunction Developing during Polymicrobial Sepsis. BioMed Research International, 2018, 2018, 1-10.	0.9	20
11	Role of complement C5a and histones in septic cardiomyopathy. Molecular Immunology, 2018, 102, 32-41.	1.0	34
12	Obesity and type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortality. Journal of Leukocyte Biology, 2018, 104, 525-534.	1.5	202
13	Selective Biological Responses of Phagocytes and Lungs to Purified Histones. Journal of Innate Immunity, 2017, 9, 300-317.	1.8	18
14	Complement and sepsis-induced heart dysfunction. Molecular Immunology, 2017, 84, 57-64.	1.0	41
15	Complement System. , 2017, , 785-812.		0
16	Understanding Immunosuppression after Sepsis. Immunity, 2017, 47, 3-5.	6.6	50
17	Diabetes and Sepsis: Risk, Recurrence, and Ruination. Frontiers in Endocrinology, 2017, 8, 271.	1.5	62
18	Complementâ€induced activation of MAPKs and Akt during sepsis: role in cardiac dysfunction. FASEB Journal, 2017, 31, 4129-4139.	0.2	39

#	Article	IF	CITATIONS
19	Bidirectional Crosstalk between C5a Receptors and the NLRP3 Inflammasome in Macrophages and Monocytes. Mediators of Inflammation, 2016, 2016, 1-11.	1.4	35
20	New Insights into Molecular Mechanisms of Immune Complex-Induced Injury in Lung. Frontiers in Immunology, 2016, 7, 86.	2.2	30
21	Melatonin alleviates acute lung injury through inhibiting the NLRP3 inflammasome. Journal of Pineal Research, 2016, 60, 405-414.	3.4	219
22	Complement: an unfinished symphony. American Journal of Physiology - Renal Physiology, 2016, 311, F66-F67.	1.3	2
23	Editorial: Blockade of PD-1 and PD-L1 restores defective innate immune responses in leukocytes from septic humans. Journal of Leukocyte Biology, 2016, 100, 1229-1231.	1.5	1
24	Complement Destabilizes Cardiomyocyte Function In Vivo after Polymicrobial Sepsis and In Vitro. Journal of Immunology, 2016, 197, 2353-2361.	0.4	47
25	Complementâ€induced activation of the cardiac NLRP3 inflammasome in sepsis. FASEB Journal, 2016, 30, 3997-4006.	0.2	91
26	The immune system's role in sepsis progression, resolution, and longâ€ŧerm outcome. Immunological Reviews, 2016, 274, 330-353.	2.8	495
27	In Sepsis, Complement Is Alive and Well*. Critical Care Medicine, 2016, 44, 1026-1027.	0.4	4
28	Anti-inflammatory interventions—what has worked, not worked, and what may work inÂtheÂfuture. Translational Research, 2016, 167, 1-6.	2.2	4
29	Therapeutic targeting of acute lung injury and acute respiratory distress syndrome. Translational Research, 2016, 167, 183-191.	2.2	148
30	Sepsis-induced immune dysfunction: can immune therapies reduce mortality?. Journal of Clinical Investigation, 2016, 126, 23-31.	3.9	461
31	The molecular fingerprint of lung inflammation after blunt chest trauma. European Journal of Medical Research, 2015, 20, 70.	0.9	37
32	Experimental Malaria in Pregnancy Induces Neurocognitive Injury in Uninfected Offspring via a C5a-C5a Receptor Dependent Pathway. PLoS Pathogens, 2015, 11, e1005140.	2.1	33
33	Experimental design of complement component 5a-induced acute lung injury (C5a-ALI): a role of CC-chemokine receptor type 5 during immune activation by anaphylatoxin. FASEB Journal, 2015, 29, 3762-3772.	0.2	43
34	Resolvins on the way to resolution. Journal of Experimental Medicine, 2015, 212, 1142-1142.	4.2	2
35	Cutting Edge: Critical Role for C5aRs in the Development of Septic Lymphopenia in Mice. Journal of Immunology, 2015, 194, 868-872.	0.4	23
36	Role of extracellular histones in the cardiomyopathy of sepsis. FASEB Journal, 2015, 29, 2185-2193.	0.2	98

#	Article	IF	CITATIONS
37	Organ distribution of histones after intravenous infusion of FITC histones or after sepsis. Immunologic Research, 2015, 61, 177-186.	1.3	36
38	Editorial Commentary: New Strategies for Treatment of Humans With Acute Lung Injury/Acute Respiratory Distress Syndrome. Clinical Infectious Diseases, 2015, 60, 596-597.	2.9	5
39	Lung inflammation and damage induced by extracellular histones. Inflammation and Cell Signaling, 2014, 1, .	1.6	11
40	Interruption of Macrophage-Derived IL-27(p28) Production by IL-10 during Sepsis Requires STAT3 but Not SOCS3. Journal of Immunology, 2014, 193, 5668-5677.	0.4	42
41	Tyrosine kinase 2 promotes sepsis-associated lethality by facilitating production of interleukin-27. Journal of Leukocyte Biology, 2014, 96, 123-131.	1.5	22
42	Persistent Neutrophil Dysfunction and Suppression of Acute Lung Injury in Mice following Cecal Ligation and Puncture Sepsis. Journal of Innate Immunity, 2014, 6, 695-705.	1.8	32
43	Induction of M2 Regulatory Macrophages through the β <sub>2</sub> -Adrenergic Receptor with Protection during Endotoxemia and Acute Lung Injury. Journal of Innate Immunity, 2014, 6, 607-618.	1.8	125
44	Inhibition of junctional adhesion molecule-A/LFA interaction attenuates leukocyte trafficking and inflammation in brain ischemia/reperfusion injury. Neurobiology of Disease, 2014, 67, 57-70.	2.1	72
45	Protein-based therapies for acute lung injury: targeting neutrophil extracellular traps. Expert Opinion on Therapeutic Targets, 2014, 18, 703-714.	1.5	46
46	Critical Role for the NLRP3 Inflammasome during Acute Lung Injury. Journal of Immunology, 2014, 192, 5974-5983.	0.4	255
47	Acute lung injury and the role of histones. Translational Respiratory Medicine, 2014, 2, 1.	3.8	35
48	Modulation of inflammation by interleukin-27. Journal of Leukocyte Biology, 2013, 94, 1159-1165.	1.5	85
49	The Bipolar Role of miR-466l in Inflammation. Immunity, 2013, 39, 801-802.	6.6	1
50	Regulation of IL-17 Family Members by Adrenal Hormones During Experimental Sepsis in Mice. American Journal of Pathology, 2013, 182, 1124-1130.	1.9	25
51	The inflammatory response in sepsis. Trends in Immunology, 2013, 34, 129-136.	2.9	406
52	Extracellular histones are essential effectors of C5aR―and C5L2â€mediated tissue damage and inflammation in acute lung injury. FASEB Journal, 2013, 27, 5010-5021.	0.2	188
53	CD11c+ Alveolar Macrophages are a Source of IL-23 During Lipopolysaccharide-Induced Acute Lung Injury. Shock, 2013, 39, 447-452.	1.0	38
54	Regulatory effects of C5a on IL-17A, IL-17F, and IL-23. Frontiers in Immunology, 2013, 3, 387.	2.2	30

#	Article	IF	CITATIONS
55	Changes and Regulation of the C5a Receptor on Neutrophils during Septic Shock in Humans. Journal of Immunology, 2013, 190, 4215-4225.	0.4	85
56	The interaction between <scp>C</scp> 5a and both <scp>C</scp> 5a <scp>R</scp> and <scp>C</scp> 5 <scp>L</scp> 2 receptors is required for production of <scp>G</scp> â€ <scp>CSF</scp> during acute inflammation. European Journal of Immunology, 2013, 43, 1907-1913.	1.6	44
57	Zonulin as prehaptoglobin2 regulates lung permeability and activates the complement system. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2013, 304, L863-L872.	1.3	57
58	An endogenous factor mediates shock-induced injury. Nature Medicine, 2013, 19, 1368-1369.	15.2	14
59	Neuroendocrine Regulation Of The IL-27-Dependent Immune Response In Macrophages. Blood, 2013, 122, 3460-3460.	0.6	0
60	Antiâ€inflammatory effects of β <sub>2</sub> adrenergic receptor agonists in experimental acute lung injury. FASEB Journal, 2012, 26, 2137-2144.	0.2	84
61	Manipulation of the Complement System for Benefit in Sepsis. Critical Care Research and Practice, 2012, 2012, 1-8.	0.4	25
62	Complement Activation Product C5a Is a Selective Suppressor of TLR4-Induced, but Not TLR3-Induced, Production of IL-27(p28) from Macrophages. Journal of Immunology, 2012, 188, 5086-5093.	0.4	47
63	New approaches to the study of sepsis. EMBO Molecular Medicine, 2012, 4, 1234-1243.	3.3	86
64	Fingerprinting of the TLR4-induced acute inflammatory response. Experimental and Molecular Pathology, 2012, 93, 319-323.	0.9	22
65	Evidence for antiâ€inflammatory effects of C5a on the innate ILâ€17A/ILâ€23 axis. FASEB Journal, 2012, 26, 1640-1651.	0.2	62
66	A Historical Perspective on Sepsis. American Journal of Pathology, 2012, 181, 2-7.	1.9	35
67	Therapeutic potential of targeting ILâ€17 and ILâ€23 in sepsis. Clinical and Translational Medicine, 2012, 1, 4.	1.7	37
68	New developments in C5a receptor signaling. Cell Health and Cytoskeleton, 2012, 4, 73.	0.7	42
69	Interactions between coagulation and complement—their role in inflammation. Seminars in Immunopathology, 2012, 34, 151-165.	2.8	393
70	Role of C3, C5 and Anaphylatoxin Receptors in Acute Lung Injury and in Sepsis. Advances in Experimental Medicine and Biology, 2012, 946, 147-159.	0.8	129
71	Role of Endothelial Chemokines and Their Receptors during Inflammation. Journal of Investigative Surgery, 2011, 24, 18-27.	0.6	110
72	Immunosuppression in Sepsis. JAMA - Journal of the American Medical Association, 2011, 306, 2618.	3.8	60

#	Article	IF	CITATIONS
73	The Outcome of Polymicrobial Sepsis Is Independent of T and B CellS. Shock, 2011, 36, 396-401.	1.0	28
74	Oxidants and Redox Signaling in Acute Lung Injury. , 2011, 1, 1365-1381.		63
75	The complement system. Cell and Tissue Research, 2011, 343, 227-235.	1.5	686
76	Disturbances of the hypothalamic-pituitary-adrenal axis and plasma electrolytes during experimental sepsis. Annals of Intensive Care, 2011, 1, 53.	2.2	20
77	Complement dependency of cardiomyocyte release of mediators during sepsis. FASEB Journal, 2011, 25, 2500-2508.	0.2	48
78	MyD88â€dependent production of ILâ€17F is modulated by the anaphylatoxin C5a <i>via</i> the Akt signaling pathway. FASEB Journal, 2011, 25, 4222-4232.	0.2	28
79	Do MDL-1+ cells play a broad role in acute inflammation?. Journal of Clinical Investigation, 2011, 121, 4234-4237.	3.9	2
80	Role of zonulin as prehaptoglobin2 in acute lung injury. FASEB Journal, 2011, 25, .	0.2	1
81	Oxidative stress: acute and progressive lung injury. Annals of the New York Academy of Sciences, 2010, 1203, 53-59.	1.8	131
82	Role of C5 Activation Products in Sepsis. Scientific World Journal, The, 2010, 10, 2395-2402.	0.8	29
83	The Harmful Role of C5a on Innate Immunity in Sepsis. Journal of Innate Immunity, 2010, 2, 439-445.	1.8	158
84	Attenuation of IgG immune complexâ€induced acute lung injury by silencing C5aR in lung epithelial cells. FASEB Journal, 2009, 23, 3808-3818.	0.2	45
85	Cross-Talk between TLR4 and FcγReceptorIII (CD16) Pathways. PLoS Pathogens, 2009, 5, e1000464.	2.1	77
86	Sepsis, complement and the dysregulated inflammatory response. Journal of Cellular and Molecular Medicine, 2009, 13, 4154-4160.	1.6	62
87	Functions of C5a receptors. Journal of Molecular Medicine, 2009, 87, 375-378.	1.7	104
88	The sepsis seesaw: seeking a heart salve. Nature Medicine, 2009, 15, 497-498.	15.2	33
89	Immunodesign of experimental sepsis by cecal ligation and puncture. Nature Protocols, 2009, 4, 31-36.	5.5	1,535
90	Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis. Critical Care, 2009, 13, R12.	2.5	87

#	Article	IF	CITATIONS
91	The First Fifty Years in Research. Annual Review of Pathology: Mechanisms of Disease, 2009, 4, 1-18.	9.6	1
92	Upregulation of Phagocyte-Derived Catecholamines Augments the Acute Inflammatory Response. PLoS ONE, 2009, 4, e4414.	1.1	134
93	The Role of Complement in Sepsis. , 2009, , 794-798.		0
94	Functional roles for C5a receptors in sepsis. Nature Medicine, 2008, 14, 551-557.	15.2	364
95	Harmful molecular mechanisms in sepsis. Nature Reviews Immunology, 2008, 8, 776-787.	10.6	1,035
96	Mechanisms of neutrophil-mediated injury. Clinical and Experimental Immunology, 2008, 93, 2-2.	1.1	3
97	On being a pathologist. Human Pathology, 2008, 39, 1719-1724.	1.1	0
98	Ability of Antioxidant Liposomes to Prevent Acute and Progressive Pulmonary Injury. Antioxidants and Redox Signaling, 2008, 10, 963-972.	2.5	55
99	Acute Lung Injury Induced by Lipopolysaccharide Is Independent of Complement Activation. Journal of Immunology, 2008, 180, 7664-7672.	0.4	130
100	C5 deficiency and C5a or C5aR blockade protects against cerebral malaria. Journal of Experimental Medicine, 2008, 205, 1133-1143.	4.2	89
101	Functions of the complement components C3 and C5 during sepsis. FASEB Journal, 2008, 22, 3483-3490.	0.2	64
102	Role of the complement in experimental sepsis. Journal of Leukocyte Biology, 2008, 83, 467-470.	1.5	45
103	Adverse functions of ILâ€17A in experimental sepsis. FASEB Journal, 2008, 22, 2198-2205.	0.2	177
104	Molecular Events in the Cardiomyopathy of Sepsis. Molecular Medicine, 2008, 14, 327-336.	1.9	106
105	The Complement Anaphylatoxin C5a Induces Apoptosis in Adrenomedullary Cells during Experimental Sepsis. PLoS ONE, 2008, 3, e2560.	1.1	52
106	Functional Roles for C5a Receptors in Sepsis. FASEB Journal, 2008, 22, 48.10.	0.2	0
107	C5a-Blockade Improves Burn-Induced Cardiac Dysfunction. Journal of Immunology, 2007, 178, 7902-7910.	0.4	43

7

#	Article	IF	CITATIONS
109	The Phosphatidylinositol 3-Kinase Signaling Pathway Exerts Protective Effects during Sepsis by Controlling C5a-Mediated Activation of Innate Immune Functions. Journal of Immunology, 2007, 178, 5940-5948.	0.4	57
110	Complement-related molecular events in sepsis leading to heart failure. Molecular Immunology, 2007, 44, 95-102.	1.0	48
111	The disconnect between animal models of sepsis and human sepsis. Journal of Leukocyte Biology, 2007, 81, 137-143.	1.5	325
112	Role of Oxidants in Lung Injury During Sepsis. Antioxidants and Redox Signaling, 2007, 9, 1991-2002.	2.5	203
113	Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice. Journal of Neuroinflammation, 2007, 4, 13.	3.1	98
114	STAT3 and suppressor of cytokine signaling 3: potential targets in lung inflammatory responses. Expert Opinion on Therapeutic Targets, 2007, 11, 869-880.	1.5	66
115	The Role of the Endothelium in Systemic Inflammatory Response Syndrome and Sepsis. , 2007, , 1294-1302.		0
116	The curiosity of IL-15. Nature Medicine, 2007, 13, 903-904.	15.2	9
117	Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature, 2007, 449, 721-725.	13.7	396
118	In Vivo Biological Responses in the Presence or Absence of C3. , 2007, 598, 240-250.		1
119	Better Understanding of Organ Dysfunction Requires Proteomic Involvement. Journal of Proteome Research, 2006, 5, 1060-1062.	1.8	15
120	Complement in lung disease. Autoimmunity, 2006, 39, 387-394.	1.2	54
121	In vivo regulation of neutrophil apoptosis by C5a during sepsis. Journal of Leukocyte Biology, 2006, 80, 1575-1583.	1.5	65
122	C5a, a Therapeutic Target in Sepsis. Recent Patents on Anti-infective Drug Discovery, 2006, 1, 57-65.	0.5	28
123	Generation of C5a in the absence of C3: a new complement activation pathway. Nature Medicine, 2006, 12, 682-687.	15.2	845
124	New Insights into Cellular Mechanisms During Sepsis. Immunologic Research, 2006, 34, 133-142.	1.3	33
125	Reduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activation. BMC Neuroscience, 2006, 7, 55.	0.8	82
126	Attenuation of half sulfur mustard gas-induced acute lung injury in rats. Journal of Applied Toxicology, 2006, 26, 126-131.	1.4	89

#	Article	IF	CITATIONS
127	Adenovirus-Mediated In Vivo Silencing of Anaphylatoxin Receptor C5aR. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-9.	3.0	8
128	Adenoviral-Mediated Overexpression of SOCS3 Enhances IgG Immune Complex-Induced Acute Lung Injury. Journal of Immunology, 2006, 177, 612-620.	0.4	33
129	Divergent Signaling Pathways in Phagocytic Cells during Sepsis. Journal of Immunology, 2006, 177, 1306-1313.	0.4	33
130	REGULATION OF LUNG INFLAMMATION IN THE MODEL OF IGG IMMUNE-COMPLEX INJURY. Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 215-242.	9.6	51
131	An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. Journal of Experimental Medicine, 2006, 203, 53-61.	4.2	166
132	HARMFUL AND PROTECTIVE ROLES OF NEUTROPHILS IN SEPSIS. Shock, 2005, 24, 40-47.	1.0	120
133	EVALUATION OF ENDOTOXIN MODELS FOR THE STUDY OF SEPSIS. Shock, 2005, 24, 7-11.	1.0	161
134	Complement-induced impairment of the innate immune system during sepsis. Current Infectious Disease Reports, 2005, 7, 349-354.	1.3	8
135	Evidence for a functional role of the second C5a receptor C5L2. FASEB Journal, 2005, 19, 1003-1005.	0.2	130
136	Changes in the Novel Orphan, C5a Receptor (C5L2), during Experimental Sepsis and Sepsis in Humans. Journal of Immunology, 2005, 174, 1104-1110.	0.4	73
137	Relationship of Acute Lung Inflammatory Injury to Fas/FasL System. American Journal of Pathology, 2005, 166, 685-694.	1.9	71
138	Chapter 12 Endothelial cell injury and defense. Advances in Molecular and Cell Biology, 2005, , 335-364.	0.1	1
139	ROLE OF C5A IN INFLAMMATORY RESPONSES. Annual Review of Immunology, 2005, 23, 821-852.	9.5	855
140	Regulatory role of C5a in LPSâ€induced ILâ€6 production by neutrophils during sepsis. FASEB Journal, 2004, 18, 1-16.	0.2	142
141	Regulatory Role of C5a on Macrophage Migration Inhibitory Factor Release from Neutrophils. Journal of Immunology, 2004, 173, 1355-1359.	0.4	66
142	Role of C5a???C5aR Interaction in Sepsis. Shock, 2004, 21, 1-7.	1.0	93
143	Stat3 Activation in Acute Lung Injury. Journal of Immunology, 2004, 172, 7703-7712.	0.4	95
144	The dark side of C5a in sepsis. Nature Reviews Immunology, 2004, 4, 133-142.	10.6	383

#	Article	IF	CITATIONS
145	Complement-induced impairment of the innate immune system during sepsis. Current Allergy and Asthma Reports, 2004, 4, 359-364.	2.4	7
146	Selectin Inhibition Modulates Akt/MAPK Signaling and Chemokine Expression After Liver Ischemia–Reperfusion. Journal of Investigative Surgery, 2004, 17, 303-313.	0.6	38
147	Mechanisms of inflammatory response syndrome in sepsis. Drug Discovery Today Disease Mechanisms, 2004, 1, 345-350.	0.8	9
148	C5a-Induced Gene Expression in Human Umbilical Vein Endothelial Cells. American Journal of Pathology, 2004, 164, 849-859.	1.9	152
149	Disturbed Homeostasis of Lung Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 During Sepsis. American Journal of Pathology, 2004, 164, 1435-1445.	1.9	57
150	Novel Chemokine Responsiveness and Mobilization of Neutrophils during Sepsis. American Journal of Pathology, 2004, 165, 2187-2196.	1.9	132
151	Novel strategies for the treatment of sepsis. Nature Medicine, 2003, 9, 517-524.	15.2	769
152	Regulation by C5a of Neutrophil Activation during Sepsis. Immunity, 2003, 19, 193-202.	6.6	99
153	Neutrophil C5a receptor and the outcome in a rat model of sepsis. FASEB Journal, 2003, 17, 1-17.	0.2	73
154	A key role of C5a/C5aR activation for the development of sepsis. Journal of Leukocyte Biology, 2003, 74, 966-970.	1.5	43
155	Anti-complement Strategies in Experimental Sepsis. Scandinavian Journal of Infectious Diseases, 2003, 35, 601-603.	1.5	17
156	Structure-Function Relationships of Human C5a and C5aR. Journal of Immunology, 2003, 170, 6115-6124.	0.4	52
157	Protective Effects of IL-6 Blockade in Sepsis Are Linked to Reduced C5a Receptor Expression. Journal of Immunology, 2003, 170, 503-507.	0.4	301
158	Anti-inflammatory strategies for the treatment of sepsis. Expert Opinion on Biological Therapy, 2003, 3, 339-350.	1.4	29
159	Murine Complement Interactions withPseudomonas aeruginosaand Their Consequences During Pneumonia. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 432-438.	1.4	44
160	The enigma of sepsis. Journal of Clinical Investigation, 2003, 112, 460-467.	3.9	281
161	The enigma of sepsis. Journal of Clinical Investigation, 2003, 112, 460-467.	3.9	499
162	Complement-Induced Impairment of Innate Immunity During Sepsis. Journal of Immunology, 2002, 169, 3223-3231.	0.4	178

#	Article	IF	CITATIONS
163	Protection of innate immunity by C5aR antagonist in septic mice. FASEB Journal, 2002, 16, 1567-1574.	0.2	152
164	Altered Neutrophil Trafficking During Sepsis. Journal of Immunology, 2002, 169, 307-314.	0.4	66
165	Expression and Function of C5a Receptor in Mouse Microvascular Endothelial Cells. Journal of Immunology, 2002, 169, 5962-5970.	0.4	145
166	C5a receptor and thymocyte apoptosis in sepsis. FASEB Journal, 2002, 16, 887-888.	0.2	84
167	Expression and Function of the C5a Receptor in Rat Alveolar Epithelial Cells. Journal of Immunology, 2002, 168, 1919-1925.	0.4	96
168	Role of nitric oxide in acute lung inflammation: Lessons learned from the inducible nitric oxide synthase knockout mouse*. Critical Care Medicine, 2002, 30, 1960-1968.	0.4	42
169	Anti-C5a Ameliorates Coagulation/Fibrinolytic Protein Changes in a Rat Model of Sepsis. American Journal of Pathology, 2002, 160, 1867-1875.	1.9	152
170	Activator Protein-1 Activation in Acute Lung Injury. American Journal of Pathology, 2002, 161, 275-282.	1.9	41
171	Generation of C5a by Phagocytic Cells. American Journal of Pathology, 2002, 161, 1849-1859.	1.9	206
172	Mediators and regulation of neutrophil accumulation in inflammatory responses in lung: insights from the lgG immune complex model 1,2 1This article is part of a series of reviews on "Reactive Oxygen and Nitrogen in Inflammation.―The full list of papers may be found on the homepage of the journal. 2Guest Editor: Giuseppe Poli. Free Radical Biology and Medicine, 2002, 33, 303-310.	1.3	135
173	Protection from half-mustard-gas-induced acute lung injury in the rat. Journal of Applied Toxicology, 2002, 22, 257-262.	1.4	76
174	Endogenous regulation of the acute inflammatory response. Molecular and Cellular Biochemistry, 2002, 234/235, 225-228.	1.4	52
175	Increased C5a receptor expression in sepsis. Journal of Clinical Investigation, 2002, 110, 101-108.	3.9	141
176	Increased C5a receptor expression in sepsis. Journal of Clinical Investigation, 2002, 110, 101-108.	3.9	103
177	Endogenous regulation of the acute inflammatory response. Molecular and Cellular Biochemistry, 2002, 234-235, 225-8.	1.4	18
178	Molecular Signatures of Sepsis. American Journal of Pathology, 2001, 159, 1199-1209.	1.9	190
179	Exogenous and Endogenous Nitric Oxide but Not iNOS Inhibition Improves Function and Survival of Ischemically Injured Livers. Journal of Investigative Surgery, 2001, 14, 267-273.	0.6	27
180	Neutrophil Depletion and Chemokine Response after Liver Ischemia and Reperfusion. Journal of Investigative Surgery, 2001, 14, 99-107.	0.6	35

#	Article	IF	CITATIONS
181	Systemic and lung physiological changes in rats after intravascular activation of complement. Journal of Applied Physiology, 2001, 90, 2289-2295.	1.2	27
182	Regulation of experimental lung inflammation. Respiration Physiology, 2001, 128, 17-22.	2.8	69
183	Protective effects of anti 5a peptide antibodies in experimental sepsis. FASEB Journal, 2001, 15, 568-570.	0.2	124
184	Role of C5a in Multiorgan Failure During Sepsis. Journal of Immunology, 2001, 166, 1193-1199.	0.4	205
185	Regulatory Effects of Eotaxin on Acute Lung Inflammatory Injury. Journal of Immunology, 2001, 166, 5208-5218.	0.4	24
186	Role of IL-18 in Acute Lung Inflammation. Journal of Immunology, 2001, 167, 7060-7068.	0.4	94
187	Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. Journal of Clinical Investigation, 2000, 106, 1271-1280.	3.9	143
188	Regulation of inflammatory vascular damage. , 2000, 190, 343-348.		145
189	Role of CC Chemokines (Macrophage Inflammatory Protein-1β, Monocyte Chemoattractant Protein-1,) Tj ETQq1	1 0.78431	.4 rgBT /Ove
190	Adhesion Molecules in Liver Ischemia and Reperfusion. Journal of Surgical Research, 2000, 94, 185-194.	0.8	62
191	Anti-Inflammatory Effects of Mutant Forms of Secretory Leukocyte Protease Inhibitor. American Journal of Pathology, 2000, 156, 1033-1039.	1.9	58
192	Leukocyte Recruitment and the Acute Inflammatory Response. Brain Pathology, 2000, 10, 127-135.	2.1	89
193	Regulation of inflammatory vascular damage. , 2000, 190, 343.		4
194	Roles for C-X-C chemokines and C5a in lung injury after hindlimb ischemia-reperfusion. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 276, L57-L63.	1.3	30
195	ENDOTHELIAL CELL DETERMINANTS OF SUSCEPTIBILITY TO NEUTROPHIL-MEDIATED KILLING. Shock, 1999, 12, 111-117.	1.0	30
196	Essential Role of Alveolar Macrophages in Intrapulmonary Activation of NF- κ B. American Journal of Respiratory Cell and Molecular Biology, 1999, 20, 692-698.	1.4	121
197	Protective effects of C5a blockade in sepsis. Nature Medicine, 1999, 5, 788-792.	15.2	385
198	Requirement for interleukin-12 in the pathogenesis of warm hepatic ischemia/reperfusion injury in mice. Hepatology, 1999, 30, 1448-1453.	3.6	104

#	Article	IF	CITATIONS
199	Inhibition of NF-κB Activation and Augmentation of IκBβ by Secretory Leukocyte Protease Inhibitor during Lung Inflammation. American Journal of Pathology, 1999, 154, 239-247.	1.9	154
200	Synergistic Enhancement of Chemokine Generation and Lung Injury by C5a or the Membrane Attack Complex of Complement. American Journal of Pathology, 1999, 154, 1513-1524.	1.9	46
201	Molecular Cloning and Characterization of a Novel Human CC Chemokine, SCYA26. Genomics, 1999, 58, 313-317.	1.3	13
202	Regulatory effects of interleukin-11 during acute lung inflammatory injury. Journal of Leukocyte Biology, 1999, 66, 151-157.	1.5	17
203	Role of chemotactic factors in neutrophil activation after thermal injury in rats. Cellular and Molecular Neurobiology, 1998, 18, 609-620.	1.7	26
204	Neutrophil adhesion to human endothelial cells is induced by the membrane attack complex: the roles of P-selectin and platelet activating factor. Inflammation, 1998, 22, 583-598.	1.7	52
205	Cytokine and adhesion molecule requirements for lung injury induced by anti-glomerular basement membrane antibody. Inflammation, 1998, 22, 403-417.	1.7	6
206	Heterogeneity of Vascular Endothelial Cells: Differences in Susceptibility to Neutrophil-mediated Injury. Microvascular Research, 1998, 56, 203-211.	1.1	55
207	Differing Patterns of P-Selectin Expression in Lung Injury. American Journal of Pathology, 1998, 153, 1113-1122.	1.9	32
208	Role of complement in in vitro and in vivo lung inflammatory reactions. Journal of Leukocyte Biology, 1998, 64, 40-48.	1.5	59
209	Blood mononuclear cell production of TNF-α and IL-8: engagement of different signal transduction pathways including the p42 MAP kinase pathway. Journal of Leukocyte Biology, 1998, 64, 124-133.	1.5	16
210	A sulfatide receptor distinct from L-selectin is involved in lymphocyte activation. FEBS Letters, 1997, 418, 310-314.	1.3	15
211	Recruitment of inflammatory cells into lung: Roles of cytokines, adhesion molecules, and complement. Translational Research, 1997, 129, 400-404.	2.4	39
212	Cytokine responses of human blood monocytes stimulated with Igs. Inflammation, 1997, 21, 501-517.	1.7	24
213	Role of Complement, Chemokines, & Regulatory Cytokines in Acute Lung Injury. Annals of the New York Academy of Sciences, 1996, 796, 104-112.	1.8	136
214	Inflammatory Mediators, Cytokines, and Adhesion Molecules in Pulmonary Inflammation and Injury. Advances in Immunology, 1996, 62, 257-304.	1.1	95
215	The role of cytokines and adhesion molecules in the development of inflammatory injury. Trends in Molecular Medicine, 1995, 1, 40-45.	2.6	126
216	Adhesion molecules and inflammatory injury. FASEB Journal, 1994, 8, 504-512.	0.2	936

#	Article	IF	CITATIONS
217	Protective effects of oligosaccharides in P-selectin-dependent lung injury. Nature, 1993, 364, 149-151.	13.7	335
218	Mechanism of Neutrophil-induced Xanthine Dehydrogenase to Xanthine Oxidase Conversion in Endothelial Cells: Evidence of a Role for Elastase. American Journal of Respiratory Cell and Molecular Biology, 1992, 6, 270-278.	1.4	73
219	Hydrogen peroxide-induced cell and tissue injury: Protective effects of Mn2+. Inflammation, 1991, 15, 291-301.	1.7	37
220	Effects of Adenosine on Inositol 1,4,5-Trisphosphate Formation and Intracellular Calcium Changes in Formyl-Met-Leu-Phe-Stimulated Human Neutrophils. Journal of Leukocyte Biology, 1990, 48, 281-283.	1.5	24
221	lloprost Inhibits Neutrophil-induced Lung Injury and Neutrophil Adherence to Endothelial Monolayers. American Journal of Respiratory Cell and Molecular Biology, 1990, 3, 301-309.	1.4	83
222	Mediatorâ€induced activation of xanthine oxidase in endothelial cells. FASEB Journal, 1989, 3, 2512-2518.	0.2	213
223	Rapid induction of neutrophil–endothelial adhesion by endothelial complement fixation. Nature, 1989, 339, 314-317.	13.7	151
224	Measurement of Intracellular Fluorescence of Human Monocytes Relative to Oxidative Metabolism. Journal of Leukocyte Biology, 1988, 43, 304-310.	1.5	123
225	Formyl peptide chemotaxis receptors on the rat neutrophil: Experimental evidence for negative cooperativity. Journal of Cellular Biochemistry, 1985, 27, 359-375.	1.2	15
226	A Comparative Study of Pulmonary Fibrosis Induced by Bleomycin and an O2 Metabolite Producing Enzyme System. Chest, 1983, 83, 44S-45S.	0.4	20
227	Suppression of acute and chronic inflammation by orally administered prostaglandins. Arthritis and Rheumatism, 1981, 24, 1151-1158.	6.7	49
228	Acute Immunologic Pulmonary Alveolitis. Journal of Clinical Investigation, 1974, 54, 349-357.	3.9	222
229	THE PHLOGISTIC ROLE OF C3 LEUKOTACTIC FRAGMENTS IN MYOCARDIAL INFARCTS OF RATS. Journal of Experimental Medicine, 1971, 133, 885-900.	4.2	378
230	Complement-derived leukotactic factors in inflammatory synovial fluids of humans. Journal of Clinical Investigation, 1971, 50, 606-616.	3.9	173
231	The production by antigen-stimulated lymphocytes of a leukotactic factor distinct from migration inhibitory factor. Cellular Immunology, 1970, 1, 162-174.	1.4	215
232	THE REQUIREMENT OF SERINE ESTERASE FUNCTION IN COMPLEMENT-DEPENDENT ERYTHROPHAGOCYTOSIS. Journal of Experimental Medicine, 1969, 130, 745-764.	4.2	55
233	ESTERASES OF THE POLYMORPHONUCLEAR LEUKOCYTE CAPABLE OF HYDROLYZING ACETYL DL-PHENYL-ALANINE ß-NAPHTHYL ESTER. Journal of Experimental Medicine, 1969, 129, 569-584.	4.2	35
234	THE DEACTIVATION OF RABBIT NEUTROPHILS BY CHEMOTACTIC FACTOR AND THE NATURE OF THE ACTIVATABLE ESTERASE. Journal of Experimental Medicine, 1968, 127, 693-709.	4.2	258

#	Article	IF	CITATIONS
235	MECHANISMS OF THE INHIBITION OF CHEMOTAXIS BY PHOSPHONATE ESTERS. Journal of Experimental Medicine, 1967, 125, 1001-1020.	4.2	101
236	PARTIAL BIOCHEMICAL CHARACTERIZATION OF THE ACTIVATED ESTERASE REQUIRED IN THE COMPLEMENT-DEPENDENT CHEMOTAXIS OF RABBIT POLYMORPHONUCLEAR LEUKOCYTES. Journal of Experimental Medicine, 1967, 125, 1021-1030.	4.2	55
237	GENERATION OF CHEMOTACTIC ACTIVITY IN RABBIT SERUM BY PLASMINOGEN-STREPTOKINASE MIXTURES. Journal of Experimental Medicine, 1967, 126, 149-158.	4.2	56
238	THE CHEMOSUPPRESSION OF CHEMOTAXIS. Journal of Experimental Medicine, 1966, 124, 209-226.	4.2	237
239	BOUND COMPLEMENT AND IMMUNOLOGIC INJURY OF BLOOD VESSELS. Journal of Experimental Medicine, 1965, 121, 215-234.	4.2	246
240	THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO. Journal of Experimental Medicine, 1965, 122, 327-346.	4.2	421
241	STUDIES ON THE ADJUVANT ACTION OF BACTERIAL ENDOTOXINS ON ANTIBODY FORMATION. Journal of Experimental Medicine, 1959, 109, 463-474.	4.2	71
242	Acute and Chronic Inflammation. , 0, , 1-16.		11